Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.60 |
| ▸ | MC5R | P33032 | 2/20 | 0.60 |
| ▸ | MC3R | P41968 | 2/20 | 0.60 |
| ▸ | MC1R | Q01726 | 2/20 | 0.60 |
| ▸ | CXCL8 | P10145 | 6/20 | 0.58 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.56 |
| ▸ | GLP1R | P43220 | 3/20 | 0.56 |
| ▸ | GCGR | P47871 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580972 | 0.94 | KISS1R (0.63) | C5AR1IL23RKISS1RGLP1R | |
| SCHEMBL29580537 | 0.94 | KISS1R (0.63) | C5AR1IL23RKISS1RGLP1R | |
| SCHEMBL29397826 | 0.88 | CXCL8 (0.64) | MC4RMC5RMC3RMC1RCXCL8 | |
| SCHEMBL31332244 | 0.88 | CXCL8 (0.64) | MC4RMC5RMC3RMC1RCXCL8 | |
| SCHEMBL1371681 | 0.87 | MC4R (0.52) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29462886 | 0.87 | MC4R (0.68) | MC4RMC5RMC3RMC1RCXCL8 | |
| SCHEMBL29580601 | 0.87 | CALCRL (0.57) | — | |
| SCHEMBL29581453 | 0.87 | CALCRL (0.57) | — | |
| SCHEMBL30186411 | 0.87 | MC4R (0.66) | MC4RMC5RMC3RMC1RCXCL8 | |
| SCHEMBL31488939 | 0.85 | KISS1R (0.63) | MC4RMC5RMC3RMC1RCXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | MC1R, MC3R, MCHR1 | MC4R 8/4885MC5R 4/4885MC3R 2/4885 |
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | MC1R, MC3R, MCHR1 | MC4R 8/4885MC5R 4/4885MC3R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.